[Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients].
Newly developed sevelamer hydrochlorid (Sev-HCl) has been recognized to show the effective control of the hyperphosphatemia in chronic renal failure patients, without elevation of serum Ca, Mg, and Al as well. Then, Sev-HCl has been expected to evolute the vitamin D treatment, and to reduce the ectopic calcifications through lowering Ca x P products. Although, relatively high frequent abdominal adverse effects in Sev-HCl treatment were reported, including life-threatening bowel occlusions or bowel perforations. It is important to use the appropriate dose of Sev-HCl avoiding the abdominal adverse effects.
Suzuki
Masashi
M
Shinraku-En Hospital, Kidney Center.
D002118:Calcium / Q000097:blood; D004066:Digestive System Diseases / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004852:Epoxy Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D007475:Ion Exchange Resins / Q000008:administration & dosage* / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000150:complications*; D010758:Phosphorus / Q000097:blood*; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D011073:Polyamines; D011095:Polyethylenes / Q000008:administration & dosage* / Q000009:adverse effects; D000069603:Sevelamer; D014807:Vitamin D / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives
D004852:Epoxy Compounds; D007475:Ion Exchange Resins; D011073:Polyamines; D011095:Polyethylenes; D014807:Vitamin D; D010758:Phosphorus; D000069603:Sevelamer; D002118:Calcium